抗肿瘤T细胞中PRDM1基因敲除增强过继免疫治疗的疗效
该研究通过CRISPR/Cas9敲除PRDM1(Blimp-1),在反复刺激的CAR-T细胞中维持早期记忆表型和多功能细胞因子分泌,促进体内低分化记忆CAR-T细胞扩增,增强T细胞持久性和多肿瘤模型疗效,机制与记忆形成相关基因染色质可及性增强有关。
要点
- PRDM1敲除维持反复刺激CAR-T细胞的早期记忆表型和多功能细胞因子分泌。
- PRDM1敲除促进体内低分化记忆CAR-T细胞扩增,增强T细胞持久性和多肿瘤模型疗效。
- PRDM1敲除在TCR工程T细胞和肿瘤浸润淋巴细胞中同样维持早期记忆表型和细胞因子多功能性。
核心结论
- 靶向PRDM1可生成更优的抗肿瘤T细胞,可能广泛适用于过继性癌症免疫治疗。
研究设计与样本
- 研究采用CRISPR/Cas9基因敲除技术,在反复刺激的CAR工程T细胞中敲除PRDM1,并在多个肿瘤模型中评估疗效。
主要发现
- PRDM1敲除支持反复刺激的CAR-T细胞维持早期记忆表型和多功能细胞因子分泌。
- PRDM1敲除促进体内低分化记忆CAR-T细胞扩增,增强T细胞持久性并改善多个肿瘤模型中的疗效。
- PRDM1敲除的T细胞中记忆形成相关基因染色质可及性增强,获得早期记忆T细胞的基因表达谱。
- PRDM1敲除在TCR工程T细胞和肿瘤浸润淋巴细胞中同样维持早期记忆表型和细胞因子多功能性。
临床怎么用
- 作者认为靶向PRDM1可能广泛适用于过继性癌症免疫治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Adoptive cancer immunotherapy can induce objective clinical efficacy in patients with advanced cancer; however, a sustained response is achieved in a minority of cases. The persistence of infused T cells is an essential determinant of a durable therapeutic response. Antitumor T cells undergo a genome-wide remodeling of the epigenetic architecture upon repeated antigen encounters, which inevitably induces progressive T-cell differentiation and the loss of longevity. In this study, we identified PR domain zinc finger protein 1 (PRDM1) ie, Blimp-1, as a key epigenetic gene associated with terminal T-cell differentiation. The genetic knockout of PRDM1 by clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) supported the maintenance of an early memory phenotype and polyfunctional cytokine secretion in repeatedly stimulated chimeric antigen receptor (CAR)-engineered T cells. PRDM1 disruption promoted the expansion of less differentiated memory CAR-T cells in vivo, which enhanced T-cell persistence and improved therapeutic efficacy in multiple tumor models. Mechanistically, PRDM1-ablated T cells displayed enhanced chromatin accessibility of the genes that regulate memory formation, thereby leading to the acquisition of gene expression profiles representative of early memory T cells. PRDM1 knockout also facilitated maintaining an early memory phenotype and cytokine polyfunctionality in T-cell receptor-engineered T cells as well as tumor-infiltrating lymphocytes. In other words, targeting PRDM1 enabled the generation of superior antitumor T cells, which is potentially applicable to a wide range of adoptive cancer immunotherapies.
引用
- Yoshikawa T, Wu Z, Inoue S, et al. Genetic ablation of PRDM1 in antitumor T cells enhances therapeutic efficacy of adoptive immunotherapy. Blood. 2022. PMID: 34861037. doi:10.1182/blood.2021012714
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。